Acadia pharmaceuticals reports fourth quarter and full year 2024 financial results and operating overview

San diego--(business wire)--acadia pharmaceuticals inc. (nasdaq: acad) today announced its financial results for the fourth quarter and full year ended december 31, 2024. “we closed 2024 on a strong note with each of our brands achieving record revenues in the fourth quarter and well-positioned for continued growth in 2025,” said catherine owen adams, chief executive officer. “to support this growth in 2025 we will continue investing in consumer activation to drive market share expansion for nu.
ACAD Ratings Summary
ACAD Quant Ranking